Nanotechnology-based cancer therapeutics - Promise and challenge - Lessons learned through the NCI alliance for nanotechnology in cancer

Pharmaceutical Research

Volumn 28, Issue 2, 2011, Pages 273-278

  Farrell, Dorothy ^a   Ptak, Krzysztof ^a   Panaro, Nicholas J ^b   Grodzinski, Piotr ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

drug delivery; multi functional nanoparticle carriers; nanoparticle; toxicity

Indexed keywords

CAMPTOTHECIN; DOCETAXEL; DOXORUBICIN; MACROGOL; METHOTREXATE; NANOPARTICLE; PACLITAXEL; SMALL INTERFERING RNA; TRANSFERRIN; VITRONECTIN RECEPTOR;

CANCER THERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; ENDOCYTOSIS; HUMAN; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; NANOENCAPSULATION; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; PANCREAS CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT;

ALBUMINS; ANIMALS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; HUMANS; MICE; NANOMEDICINE; NANOPARTICLES; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PACLITAXEL; RNA, SMALL INTERFERING; UNITED STATES;

EID: 79952485687     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0214-7     Document Type: Review

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn. 2006;6:307-18. (Pubitemid 44174337)
3. Laginha KM, Verwoert S, Charrois GJR, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11:6944-9. (Pubitemid 41428752)
4. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol. 2000;79:116-9.
5. Harries M, Ellis P, Harper P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J Clin Oncol. 2005;23:7768-71. (Pubitemid 46657369)
6. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (abi-007) and paclitaxel formulated in cremophor (taxol). Clin Cancer Res. 2005;11:4136-43. (Pubitemid 40791578)
7. Farrell D, Alper J, Ptak K, Panaro NJ, Grodzinski P, Barker AD. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. ACS Nano. 2010;4:589-594.
8. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161-71. (Pubitemid 40314948)
9. Heath JR, Davis ME. Nanotechnology and cancer. Annu Rev Med. 2008;59:251-65. (Pubitemid 351287936)
10. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-60. (Pubitemid 350223348)
11. Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83:761-9. (Pubitemid 351556021)
12. Shi X, Wang SH, Swanson SD, Ge S, Cao Z, Van Antwerp ME, et al. Dendrimer-functionalized shell-crosslinked iron oxide nanoparticles for in-vivo magnetic resonance imaging of tumors. Adv Mater. 2008;20:1671-8.
13. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, et al. Plga-lecithin-peg core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30:1627-34.
14. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA. 2008;105:2586-91. (Pubitemid 351520557)
15. Davis M. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev. 2009;61:1189-92.
16. Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CHJ, Alabi CA, et al. Pharmacokinetics and tumor dynamics of the nanoparticle it-101 from pet imaging and tumor histological measurements. Proc Natl Acad Sci. 2009;106:11394-9.
17. Schluep T, Gunawan P, Ma L, Jensen GS, Duringer J, Hinton S, et al. Polymeric tubulysin-peptide nanoparticles with potent antitumoractivity. Clin Cancer Res. 2009;15:181-9.
18. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA. 2008;105:9343-8.
19. Davis M. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009;6:659-68.
20. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of sirna nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA. 2007;104:15549-54. (Pubitemid 47502954)
21. Devalapally H, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res. 2008;14:3193-203.
22. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007;67:4843-50. (Pubitemid 46910193)
23. Heidel JD, Liu JY-C, Yen Y, Zhou B, Heale BSE, Rossi JJ, et al. Potent sirna inhibitors of ribonucleotide reductase subunit rrm2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res. 2007;13:2207-15. (Pubitemid 46649891)
24. Park JH, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ, et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small. 2009;5:694-700.
25. Park JH, von Maltzahn G, Zhang L, Schwartz MP, Ruoslahti E, Bhatia SN, et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv Mater. 2008;20:1589.
26. Veiseh O, Sun C, Fang C, Bhattarai N, Gunn J, Kievit F, et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 2009;69:6200-7.
27. Veiseh O, Kievit FM, Gunn JW, Ratner BD, Zhang M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials. 2009;30:649-57.
28. Veiseh O, Gunn JW, Kievit FM, Sun C, Fang C, Lee JS, et al. Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small. 2009;5:256-64.
29. Mahmud G, Campbell CJ, Bishop KJM, Komarova YA, Chaga O, Soh S, et al. Directing cell motions on micropatterned ratchets. Nat Phys. 2009;5:606-12.
30. Mahmud G, Bishop KJM, Chegel Y, Smoukov SK, Grzybowski BA. Wet-stamped precipitant gradients control the growth of protein microcrystals in an array of nanoliter wells. J Am Chem Soc. 2008;130:2146-+.
31. McNeil SE. Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1:264-71.
32. Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2010;2:99-112.